Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre

Background Sitagliptin is a DPP-IV inhibitor and has been proven to reduce HbA1c by 0.8% when used as monotherapy and up to 2.1% when used in combination with maximum dose of metformin. Objectives To evaluate the glycemic control in patients treated with sitagliptin either as monotherapy or as...

Full description

Bibliographic Details
Main Authors: WS, Wan Juani, M., Azura Dina, S., Norlela, M., Norlaila, AW, Norasyikin, O, Ahmad Marzuki, R, Subashini, Loh, Huai Heng, Shahar, Mohammad Arif, O, Mohd Rahman, K., Nor Azmi
Format: Article
Language:English
Published: Malaysian Endocrine and Metabolic Society 2014
Subjects:
Online Access:http://irep.iium.edu.my/50065/
http://irep.iium.edu.my/50065/
http://irep.iium.edu.my/50065/4/OP-37.pdf

Similar Items